• 목록
• 답변

ARBM-101, a rare and incurable treatment of ARBORMED Co., Ltd., was introduced at an overseas symposium. The company announced the results of ARBM-101's research on
Wilson's disease animal models at the Wilson Aarhus 2022 Symposium (Ahus, Denmark), a recent Wilson's disease core group meeting.

ARBORMED's first rare genetic disease new drug ARBM-101 is being developed as an intravenous injection for patients with severe liver disease with Wilson's disease,
which has high unmet medical demand. It was introduced in 2019 by the Helmholtz Institute in Munich, Germany, the University of Iowa, the University of Michigan,
 and the University of Wisconsin.

Hans Zischka, a professor at the Helmholtz Institute who introduced ARBM-101 at the symposium, is a world-renowned expert who studied Wilson's disease animal model over 20 years ago,
 using homogeneous metanobactin peptides.

Through a joint study with Professor Hans Zishka, ARBORMED secured the results of an animal model test that shows superior copper emission efficacy than metanobactin
as well as ARBM-101 Wilson's disease treatment. According to the results of the study, ARBM-101 not only extended life expectancy due to short-term administration,
but also did not have significant side effects during dose administration, confirming drug safety.

Unlike ALXN-1840 and gene therapy drugs, which are currently in the clinical trial stage as targets for Wilson's disease, intermittent administration with a non-administrative pause
 after initial intensive administration can maintain hepatocellular copper concentration and liver levels for a long time and minimize side effects.

According to ARBORMRED, Professor Zishka's ARBM-101 study received great attention from key researchers related to Wilson's disease, clinicians, and the indication core group,
which included a group of Wilson's disease patients. In particular, he expressed expectations for the possibility of improving symptoms of severe liver disease derived from Wilson's disease,
 which cannot be solved with existing Wilson disease treatments.

Meanwhile, ARBORMED plans to present the results of the efficacy test of ARBM-101 as a paper by the end of this year and is conducting non-clinical tests with the aim of approving clinical trials
by the end of 2023. In addition to ARBM-101, GLP-toxicity tests and functional mechanism studies of non-clinical pipelines such as acute respiratory distress syndrome (ARDS)
and congenital hearing loss treatments are being conducted. In addition, it aims to be listed on the KOSDAQ by 2025.

Source: Medical Tribune (http://www.medical-tribune.co.kr)